Efficacy of Micafungin (MCFG) for Pediatric Patients of Hematological Disorder and Malignant Tumor
-
- ONUMA Masaei
- Departments of Pediatrics, Tohoku University School of Medicine
-
- KUMAKI Satoru
- Departments of Pediatrics, Tohoku University School of Medicine
-
- YOSHINARI Miyako
- Departments of Pediatric Hematology and Oncology, Tohoku University School of Medicine
-
- SATO Atsushi
- Department of Hematology and Oncology, Miyagi Children's Hospital
-
- TERUI Kiminori
- Department of Pediatrics, Hirosaki University School of Medicine
-
- KAMIO Takuya
- Department of Pediatrics, Hirosaki University School of Medicine
-
- HIRAYAMA Masashi
- Department of Pediatrics, Nakadoori General Hospital
-
- KANNO Miyako
- Department of Pediatrics, Yamagata University School of Medicine
-
- KAWAKAMI Takako
- Department of Pediatrics, Yamagata University School of Medicine
-
- MOCHIZUKI Kazuhiro
- Department of Pediatrics, Fukushima Medical University School of Medicine
-
- ITO Masaki
- Department of Pediatrics, Fukushima Medical University School of Medicine
-
- WATANABE Arata
- Department of Pediatrics, Nakadoori General Hospital
-
- ENDO Mikiya
- Department of Pediatrics, Iwate Medical Universiy
-
- MITSUI Tetsuo
- Department of Pediatrics, Yamagata University School of Medicine
-
- IMAIZUMI Masue
- Department of Hematology and Oncology, Miyagi Children's Hospital
-
- KIKUTA Atsushi
- Department of Pediatrics, Fukushima Medical University School of Medicine
-
- ITO Etsuro
- Department of Pediatrics, Hirosaki University School of Medicine
-
- TSUCHIYA Shigeru
- Departments of Pediatrics, Tohoku University School of Medicine
Bibliographic Information
- Other Title
-
- 血液・腫瘍性疾患患児における抗真菌薬ミカファンギンの有効性に関する検討
Search this article
Abstract
We performed a multicenter study to evaluate the efficacy and safety of micafungin (MCFG) in empiric and prophylactic treatment for pediatric patients with neutropenia due to hematopoietic stem cell transplantation or chemotherapy for hematological disorders and malignant tumors. In the prophylactic treatment group, all 17 patients, administered MCFG at a dose of 3.1 mg/kg (range 2.5 to 4.5 mg/kg), showed prophylactic efficacy against fungalinfection. In the empiric treatment group, 14 (70%) of 20 patients, administered MCFG at a dose of 3.8 mg/kg (range 2.6 to 6.0 mg/kg), showed improvements in infectious symptoms. None of the patients required discontinuation, although toxicity developed in 8 (19%) patients, including diarrhea and abdominal pain. This multicenter study demonstrated the effectiveness and safety of MCFG in an empiric and prophylactic treatment for pediatric patients.
Journal
-
- The Japanese Journal of Pediatric Hematology
-
The Japanese Journal of Pediatric Hematology 22 (4), 226-232, 2008
THE JAPANESE SOCIETY OF PEDIATRIC HEMATOLOGY/ONCOLOGY
- Tweet
Details 詳細情報について
-
- CRID
- 1390282679317544704
-
- NII Article ID
- 10029309484
- 130004345991
-
- NII Book ID
- AN10080852
-
- ISSN
- 18844723
- 09138706
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- CiNii Articles
- KAKEN
-
- Abstract License Flag
- Disallowed